Aardvark Therapeutics' (AARD) "Sector Perform" Rating Reaffirmed at Royal Bank Of Canada

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report)'s stock had its "sector perform" rating restated by research analysts at Royal Bank Of Canada in a research report issued on Thursday, Benzinga reports. They presently have a $6.00 target price on the stock. Royal Bank Of Canada's price objective indicates a potential upside of 9.99% from the company's previous close.

A number of other equities research analysts have also recently commented on the company. Weiss Ratings upgraded Aardvark Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, July 2nd. Wall Street Zen raised shares of Aardvark Therapeutics from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 15th. Finally, HC Wainwright restated a "neutral" rating and set a $6.00 price target on shares of Aardvark Therapeutics in a research note on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Aardvark Therapeutics currently has a consensus rating of "Hold" and a consensus price target of $15.33.

Aardvark Therapeutics Price Performance

Shares of AARD stock traded down $0.11 during mid-day trading on Thursday, hitting $5.46. 3,062 shares of the stock traded hands, compared to its average volume of 235,150. Aardvark Therapeutics has a 52-week low of $3.35 and a 52-week high of $17.94. The stock has a market cap of $119.38 million, a P/E ratio of -1.70 and a beta of 3.74. The stock's fifty day moving average is $6.20 and its two-hundred day moving average is $5.28.

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.21. As a group, equities analysts forecast that Aardvark Therapeutics will post -3.17 EPS for the current fiscal year.

Insider Activity at Aardvark Therapeutics

In other news, insider Nelson Sun sold 62,000 shares of the company's stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $5.18, for a total value of $321,160.00. Following the completion of the sale, the insider directly owned 35,475 shares of the company's stock, valued at approximately $183,760.50. This represents a 63.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 17.80% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in Aardvark Therapeutics during the 2nd quarter worth about $1,077,000. Propel Bio Management LLC acquired a new position in shares of Aardvark Therapeutics in the fourth quarter worth $609,000. Renaissance Technologies LLC acquired a new position in Aardvark Therapeutics in the first quarter worth approximately $267,000. J. Goldman & Co LP bought a new stake in Aardvark Therapeutics in the second quarter worth $233,000. Finally, Ieq Capital LLC bought a new stake in shares of Aardvark Therapeutics during the 2nd quarter worth about $221,000.

Trending Headlines about Aardvark Therapeutics

Here are the key news stories impacting Aardvark Therapeutics this week:

• Positive Sentiment: Royal Bank of Canada reaffirmed its “sector perform” rating and assigned a $6.00 price target, implying approximately 8% potential upside from the recently cited $5.55 share price. The target suggests RBC sees some recovery potential, although the neutral rating signals limited conviction. Benzinga analyst rating report
• Neutral Sentiment: Brokerages have assigned Aardvark a consensus “hold” recommendation, indicating that analysts are largely waiting for greater clarity on the company’s clinical and legal outlook.
• Negative Sentiment: A securities class action has been filed against Aardvark and certain officers and directors. The complaint covers investors who purchased shares in or traceable to the IPO, as well as securities purchased during the February 13, 2025–May 14, 2026 class period. Investors face an October 13, 2026 deadline to seek lead-plaintiff status. Bernstein Liebhard shareholder alert
• Negative Sentiment: The allegations center on claims that Aardvark overstated the safety and tolerability of its ARD-101 therapy before the Phase 3 HERO trial was paused and the FDA imposed a full clinical hold. The resulting uncertainty has contributed to sharply reduced price targets and weighs on the stock’s outlook. AARD shareholder alert

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing oral therapies for obesity, hyperphagia and related metabolic disorders. The company's approach is based on activating bitter taste receptors, which it believes may influence appetite regulation and metabolic signaling without relying on injectable therapies.

Aardvark's lead investigational product, ARD-101, is an oral small-molecule bitter taste receptor agonist being studied for conditions involving excessive hunger and food intake, including hyperphagia associated with Prader-Willi syndrome.